Show
Sort by
-
New onset inflammatory bowel disease after initiation of anti-IL-17a treatment : a case series
-
The comparative effectiveness and safety of different biologics in young (<60 years) versus elderly (≥60 years) patients with IBD : results from a real-world experience at a Belgian tertiary centre
(2024) Abstracts of the 19th Congress of ECCO Stockholm, Sweden, February 21-24, 2024. In Journal of Crohns & Colitis 18(Suppl. 1). p.i1739-i1740 -
Age-related patterns in biological therapy use and surgery among patients with IBD : insights from the Belgian PANTHER cohort
(2024) Abstracts of the 19th Congress of ECCO Stockholm, Sweden, February 21-24, 2024. In Journal of Crohns & Colitis 18(Suppl. 1). p.i1125-i1127 -
Infliximab re-challenge : could it be an option in refractory IBD patients?
-
- Conference Paper
- C3
- open access
The impact of vedolizumab on extra-intestinal manifestations in inflammatory bowel disease patients : a real-life experience of a single-centre cohort
-
Effectiveness of ustekinumab in refractory Crohn's disease : a real-life experience in a tertiary referral centre
-
- Conference Paper
- C3
- open access
Retrospective study of the effectiveness and safety of Ustekinumab in refractory Crohn's Disease
(2019) UEG Week 2019 Poster Presentations. In UNITED EUROPEAN GASTROENTEROLOGY JOURNAL 7(8, suppl.). p.644-644 -
- Conference Paper
- C3
- open access
Efficacy of Ustekinumab intensification and re-induction in Crohn’s disease patients with insufficient or loss of response
(2019) UEG Week 2019 Poster Presentations. In UNITED EUROPEAN GASTROENTEROLOGY JOURNAL 7(8, suppl.). p.645-645 -
Dialister as a microbial marker of disease activity in spondyloarthritis
-
Degree of bone marrow oedema in sacroiliac joints of patients with axial spondyloarthritis is linked to gut inflammation and male sex: results from the GIANT cohort